SK16232003A3 - Spôsob prípravy N-[3-(3-kyanopyrazolo [1,5-a]pyrimidín-7- yl)genyl]-N-etylacetamidu (zaleplonu) - Google Patents
Spôsob prípravy N-[3-(3-kyanopyrazolo [1,5-a]pyrimidín-7- yl)genyl]-N-etylacetamidu (zaleplonu) Download PDFInfo
- Publication number
- SK16232003A3 SK16232003A3 SK1623-2003A SK16232003A SK16232003A3 SK 16232003 A3 SK16232003 A3 SK 16232003A3 SK 16232003 A SK16232003 A SK 16232003A SK 16232003 A3 SK16232003 A3 SK 16232003A3
- Authority
- SK
- Slovakia
- Prior art keywords
- acid
- zaleplon
- water
- reaction medium
- mixture
- Prior art date
Links
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 229960004010 zaleplon Drugs 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 239000012429 reaction media Substances 0.000 claims abstract description 26
- FFNKBQRKZRMYCL-UHFFFAOYSA-N 5-amino-1h-pyrazole-4-carbonitrile Chemical compound NC1=NNC=C1C#N FFNKBQRKZRMYCL-UHFFFAOYSA-N 0.000 claims abstract description 19
- UXWJJVRASIHSQS-MDZDMXLPSA-N n-[3-[(e)-3-(dimethylamino)prop-2-enoyl]phenyl]-n-ethylacetamide Chemical compound CCN(C(C)=O)C1=CC=CC(C(=O)\C=C\N(C)C)=C1 UXWJJVRASIHSQS-MDZDMXLPSA-N 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 230000002378 acidificating effect Effects 0.000 claims abstract description 9
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 70
- 239000002253 acid Substances 0.000 claims description 41
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 235000011054 acetic acid Nutrition 0.000 claims description 4
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- ZMUMYMWAIXXLIY-UHFFFAOYSA-N n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-n-ethylacetamide Chemical compound CCN(C(C)=O)C1=CC=CC(C2=NC3=C(C#N)C=NN3C=C2)=C1 ZMUMYMWAIXXLIY-UHFFFAOYSA-N 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 239000011368 organic material Substances 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 150000002828 nitro derivatives Chemical class 0.000 claims description 2
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 claims description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- RRHORVAOECWFPT-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carbonitrile Chemical compound C1=CC=NC2=C(C#N)C=NN21 RRHORVAOECWFPT-UHFFFAOYSA-N 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 239000000047 product Substances 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 12
- 150000002466 imines Chemical class 0.000 description 11
- 239000003960 organic solvent Substances 0.000 description 10
- 239000012535 impurity Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- WGZYVHFXLPDNDL-UHFFFAOYSA-N 4-benzoyl-2-phenylpyrazole-3-carbonitrile Chemical compound C=1C=CC=CC=1C(=O)C(=C1C#N)C=NN1C1=CC=CC=C1 WGZYVHFXLPDNDL-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012035 limiting reagent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- ZBBUUZBCGCQPBJ-UHFFFAOYSA-N 5-amino-1h-pyrazole-4-carbonitrile;hydrochloride Chemical compound Cl.NC1=NNC=C1C#N ZBBUUZBCGCQPBJ-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FKCBLVCOSCZFHV-UHFFFAOYSA-N acetonitrile;ethanol Chemical compound CCO.CC#N FKCBLVCOSCZFHV-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011141 high resolution liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- -1 tetrahydrofuran) Chemical class 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29763501P | 2001-06-12 | 2001-06-12 | |
| PCT/US2002/018567 WO2002100828A2 (en) | 2001-06-12 | 2002-06-12 | Process for the production of zaleplon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK16232003A3 true SK16232003A3 (sk) | 2004-12-01 |
Family
ID=23147125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1623-2003A SK16232003A3 (sk) | 2001-06-12 | 2002-06-12 | Spôsob prípravy N-[3-(3-kyanopyrazolo [1,5-a]pyrimidín-7- yl)genyl]-N-etylacetamidu (zaleplonu) |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6884888B2 (is) |
| EP (1) | EP1406871A4 (is) |
| JP (1) | JP2005507858A (is) |
| KR (1) | KR20040007683A (is) |
| CN (1) | CN1537113A (is) |
| CA (1) | CA2450384A1 (is) |
| CZ (1) | CZ20033544A3 (is) |
| DE (1) | DE02778962T1 (is) |
| ES (1) | ES2223311T1 (is) |
| HR (1) | HRP20040016A2 (is) |
| HU (1) | HUP0402257A2 (is) |
| IL (1) | IL159281A0 (is) |
| IS (1) | IS7069A (is) |
| MX (1) | MXPA03011485A (is) |
| NO (1) | NO20035538D0 (is) |
| PL (1) | PL372942A1 (is) |
| SK (1) | SK16232003A3 (is) |
| TR (1) | TR200402588T3 (is) |
| WO (1) | WO2002100828A2 (is) |
| ZA (1) | ZA200309677B (is) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2450384A1 (en) * | 2001-06-12 | 2002-12-19 | Biogal Gyogyszergyar Rt. | Process for the production of zaleplon |
| US20050032818A1 (en) * | 2001-06-12 | 2005-02-10 | Entire Interest | N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide and crystalline forms of zaleplon |
| PL374176A1 (en) | 2001-08-01 | 2005-10-03 | Biogal Gyogyszergyar Rt | Process for purifying n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process |
| AU2003218058A1 (en) * | 2002-02-15 | 2003-09-04 | Teva Gyogyszergyar Reszvenytarsasag | Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom |
| PL207322B1 (pl) * | 2002-05-14 | 2010-11-30 | Adamed Społka Z Ograniczoną Odpowiedzialnością | Sposób wytwarzania zaleplonu |
| AU2002343201A1 (en) * | 2002-10-16 | 2004-05-04 | Sanmar Speciality Chemicals Limited | Synthesis of zaleplon |
| CZ293015B6 (cs) * | 2002-10-25 | 2004-01-14 | Léčiva, A.S. | Způsob výroby N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-fenyl]-acetamidu (zaleplonu) |
| KR101248123B1 (ko) * | 2003-09-04 | 2013-03-27 | 씨아이피엘에이 엘티디. | 잘레플론의 합성 |
| WO2005070931A1 (en) * | 2004-01-14 | 2005-08-04 | Mallinckrodt Inc. | Two-phase method for the synthesis of selected pyrazolopyrimidines |
| HUP0400325A3 (en) * | 2004-02-02 | 2005-11-28 | Richter Gedeon Vegyeszet | Pure n-[3-(-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethyl-acetamide, process for its preparation and intermediates |
| WO2005099712A2 (en) * | 2004-04-19 | 2005-10-27 | Sanmar Speciality Chemicals Limited | Process for preparation of n-[3-(3-cyanopyrazolo [1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide |
| WO2006070244A2 (en) * | 2004-11-22 | 2006-07-06 | Bakulesh Mafatlal Khamar | A process for the preparation of zaleplon |
| CN102816163A (zh) * | 2012-08-20 | 2012-12-12 | 四川禾邦阳光制药股份有限公司 | 扎来普隆的新晶型及制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4626538A (en) * | 1983-06-23 | 1986-12-02 | American Cyanamid Company | [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines |
| US5714607A (en) * | 1995-12-01 | 1998-02-03 | American Cyanamid Company | Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide |
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| US6384221B1 (en) * | 1999-09-02 | 2002-05-07 | Neurocrine Biosciences, Inc. | Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
| SG125971A1 (en) * | 2000-08-03 | 2006-10-30 | Wyeth Corp | Variable water hydrates of zaleplon and method forthe preparation thereof |
| AR029780A1 (es) * | 2000-12-13 | 2003-07-16 | Gador Sa | Procedimiento mejorado para la obtencion de n-[3(3-ciano-pirazolo[1,5-a]pirimidin-7-il)fenil]-n-etil-acetamida |
| CA2450384A1 (en) * | 2001-06-12 | 2002-12-19 | Biogal Gyogyszergyar Rt. | Process for the production of zaleplon |
| PL374176A1 (en) * | 2001-08-01 | 2005-10-03 | Biogal Gyogyszergyar Rt | Process for purifying n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process |
| PL207322B1 (pl) * | 2002-05-14 | 2010-11-30 | Adamed Społka Z Ograniczoną Odpowiedzialnością | Sposób wytwarzania zaleplonu |
-
2002
- 2002-06-12 CA CA002450384A patent/CA2450384A1/en not_active Abandoned
- 2002-06-12 JP JP2003503597A patent/JP2005507858A/ja active Pending
- 2002-06-12 HR HR20040016A patent/HRP20040016A2/hr not_active Application Discontinuation
- 2002-06-12 DE DE02778962T patent/DE02778962T1/de active Pending
- 2002-06-12 IL IL15928102A patent/IL159281A0/xx unknown
- 2002-06-12 PL PL02372942A patent/PL372942A1/xx not_active Application Discontinuation
- 2002-06-12 MX MXPA03011485A patent/MXPA03011485A/es not_active Application Discontinuation
- 2002-06-12 TR TR2004/02588T patent/TR200402588T3/xx unknown
- 2002-06-12 WO PCT/US2002/018567 patent/WO2002100828A2/en not_active Ceased
- 2002-06-12 ES ES02778962T patent/ES2223311T1/es active Pending
- 2002-06-12 KR KR10-2003-7016185A patent/KR20040007683A/ko not_active Ceased
- 2002-06-12 US US10/170,673 patent/US6884888B2/en not_active Expired - Fee Related
- 2002-06-12 EP EP02778962A patent/EP1406871A4/en not_active Withdrawn
- 2002-06-12 HU HU0402257A patent/HUP0402257A2/hu unknown
- 2002-06-12 CN CNA028150112A patent/CN1537113A/zh active Pending
- 2002-06-12 SK SK1623-2003A patent/SK16232003A3/sk unknown
- 2002-06-12 CZ CZ20033544A patent/CZ20033544A3/cs unknown
-
2003
- 2003-12-10 IS IS7069A patent/IS7069A/is unknown
- 2003-12-11 NO NO20035538A patent/NO20035538D0/no not_active Application Discontinuation
- 2003-12-12 ZA ZA200309677A patent/ZA200309677B/en unknown
-
2005
- 2005-02-25 US US11/067,044 patent/US20050187225A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200309677B (en) | 2004-12-13 |
| CZ20033544A3 (cs) | 2004-11-10 |
| US20030040522A1 (en) | 2003-02-27 |
| MXPA03011485A (es) | 2004-06-11 |
| ES2223311T1 (es) | 2005-03-01 |
| IL159281A0 (en) | 2004-06-01 |
| US6884888B2 (en) | 2005-04-26 |
| DE02778962T1 (de) | 2005-02-10 |
| WO2002100828A3 (en) | 2003-05-01 |
| US20050187225A1 (en) | 2005-08-25 |
| TR200402588T3 (tr) | 2004-11-22 |
| CA2450384A1 (en) | 2002-12-19 |
| EP1406871A2 (en) | 2004-04-14 |
| CN1537113A (zh) | 2004-10-13 |
| IS7069A (is) | 2003-12-10 |
| KR20040007683A (ko) | 2004-01-24 |
| HUP0402257A2 (hu) | 2005-02-28 |
| HRP20040016A2 (en) | 2004-10-31 |
| PL372942A1 (en) | 2005-08-08 |
| JP2005507858A (ja) | 2005-03-24 |
| NO20035538D0 (no) | 2003-12-11 |
| EP1406871A4 (en) | 2005-01-26 |
| WO2002100828A2 (en) | 2002-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2847728C (en) | Processes and intermediates for making a jak inhibitor | |
| EP2896617B1 (de) | Verfahren zur herstellung von substituierten (z)-alpha-fluoro-beta-amino-acrylaldehyden | |
| SK16232003A3 (sk) | Spôsob prípravy N-[3-(3-kyanopyrazolo [1,5-a]pyrimidín-7- yl)genyl]-N-etylacetamidu (zaleplonu) | |
| CA2971460A1 (en) | Synthesis of a bruton's tyrosine kinase inhibitor | |
| EA031632B1 (ru) | СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ{4,6-ДИАМИНО-2-[1-(2-ФТОРБЕНЗИЛ)-1H-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ]ПИРИМИДИН-5-ИЛ}МЕТИЛКАРБАМАТА | |
| EP2609099A2 (en) | Sitagliptin, salts and polymorphs thereof | |
| KR20180137498A (ko) | 인다졸의 합성 | |
| EP3475281A1 (en) | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives | |
| CA2783684A1 (en) | Inhibitors of diacylglycerol acyltransferase | |
| EP4153599B1 (en) | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate | |
| CN102725288A (zh) | 用于制造6-取代的1-甲基-1h-苯并咪唑衍生物的方法和所述方法的中间体 | |
| US8278484B2 (en) | Process for preparing a benzoylbenzeneacetamide derivative | |
| RU2761213C2 (ru) | Соль и полиморф фенил-пиримидонового соединения, их фармацевтическая композиция и применение | |
| AU2002348641A1 (en) | Process for the production of zaleplon | |
| Devi et al. | Synthesis and Stereochemistry of N4 Amino-1, 2, 4-Triazoles with unsymmetrical substituents at 3, 5-Positions | |
| SK59995A3 (en) | Process for preparing enantiomerically pure 6-£(4-chlorophenyl) (1h-triazol-1,2,4-triazol-1-yl) methyl|-1-methyl-1h-benzotriazole, intermediates for its production and method of its production | |
| WO2019064222A1 (en) | CRYSTALLINE FORMS OF LENALIDOMIDE | |
| US20050032818A1 (en) | N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide and crystalline forms of zaleplon | |
| EP4547253A1 (en) | Process for the preparation of tucatinib | |
| SK149393A3 (en) | 2-thienylmidazo/2,1-b/benzothiazole-3-acetic acid derivatives, method of their preparation and their therapeutical using | |
| HUP0400325A2 (hu) | Nagytisztaságú N-[3-(3-ciano-pirazolo[1,5-a]pirimidin-7-il)-fenil]-N-etil-acetamid, eljárás előállítására, valamint intermedierjei | |
| NZ747420A (en) | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |